These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 10337502

  • 1. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A, De Martini D, Flore R, Gaetani E, Gasbarrini A, Gerardino L, Pola R, Santoliquido A, Serricchio M, Tondi P, Nolfe G.
    Drugs Exp Clin Res; 1999; 25(1):29-36. PubMed ID: 10337502
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of chronic arterial occlusive disease of the lower limbs with propionyl-1-carnitine in elderly patients].
    Terranova R, Luca S.
    Minerva Med; 2001 Feb; 92(1):61-6. PubMed ID: 11317141
    [Abstract] [Full Text] [Related]

  • 3. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
    Brevetti G, Perna S, Sabbá C, Martone VD, Condorelli M.
    J Am Coll Cardiol; 1995 Nov 15; 26(6):1411-6. PubMed ID: 7594063
    [Abstract] [Full Text] [Related]

  • 4. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
    Hiatt WR, Creager MA, Amato A, Brass EP.
    J Cardiopulm Rehabil Prev; 2011 Nov 15; 31(2):125-32. PubMed ID: 20861750
    [Abstract] [Full Text] [Related]

  • 5. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C, Antignani PL, Schachter I, Koverech A, Messano M, Virmani A.
    Ann Vasc Surg; 2008 Nov 15; 22(4):552-8. PubMed ID: 18502605
    [Abstract] [Full Text] [Related]

  • 6. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.
    Andreozzi GM.
    Expert Opin Pharmacother; 2009 Nov 15; 10(16):2697-707. PubMed ID: 19827991
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
    Riccioni C, Sarcinella R, Palermo G, Izzo A, Liguori M, Koverech A, Messano M, Virmani A.
    Int Angiol; 2008 Jun 15; 27(3):253-9. PubMed ID: 18506129
    [Abstract] [Full Text] [Related]

  • 8. [Comparison between L-propionyl carnitine and physical-rehabilitative exercise in diabetics with obliterative arteriopathy of the legs (Fontaine's stage IIa)].
    Costanza G, Di Salvo A, Barone G, Verruso G, Zamueli M, Marchese G.
    Minerva Cardioangiol; 1999 Dec 15; 47(12):649-50. PubMed ID: 10670244
    [No Abstract] [Full Text] [Related]

  • 9. The action of propionyl-L-carnitine on the vasal endothelium: increased t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study.
    Pola P, De Martini D, Gerardino L, De Rossi S, Tondi P.
    Drugs Exp Clin Res; 1992 Dec 15; 18(8):343-8. PubMed ID: 1292917
    [Abstract] [Full Text] [Related]

  • 10. Carnitine and peripheral arterial disease.
    Hiatt WR.
    Ann N Y Acad Sci; 2004 Nov 15; 1033():92-8. PubMed ID: 15591006
    [Abstract] [Full Text] [Related]

  • 11. [The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure].
    Pucciarelli G, Mastursi M, Latte S, Sacra C, Setaro A, Lizzadro A, Nolfe G.
    Clin Ter; 1992 Nov 15; 141(11):379-84. PubMed ID: 1493661
    [Abstract] [Full Text] [Related]

  • 12. Propionyl-L-carnitine.
    Wiseman LR, Brogden RN.
    Drugs Aging; 1998 Mar 15; 12(3):243-8; discussion 249-50. PubMed ID: 9534023
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
    Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C.
    Ann N Y Acad Sci; 2004 Nov 15; 1033():79-91. PubMed ID: 15591005
    [Abstract] [Full Text] [Related]

  • 14. [Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride].
    Seboldt H.
    Fortschr Med; 1980 Feb 21; 98(7):257-60. PubMed ID: 6767648
    [Abstract] [Full Text] [Related]

  • 15. [Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].
    Branchereau A, Rouffy J.
    J Mal Vasc; 1995 Feb 21; 20(1):21-7. PubMed ID: 7745355
    [Abstract] [Full Text] [Related]

  • 16. Propionyl-L-carnitine for intermittent claudication.
    Deckert J.
    J Fam Pract; 1997 Jun 21; 44(6):533-4. PubMed ID: 9191622
    [No Abstract] [Full Text] [Related]

  • 17. Rheological activity of propionyl L-carnitine.
    Pola P, Flore R, Tondi P, Nolfe G.
    Drugs Exp Clin Res; 1991 Jun 21; 17(3):191-6. PubMed ID: 1914846
    [Abstract] [Full Text] [Related]

  • 18. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA, Krantz MJ, Hiatt WR.
    Vasc Med; 2012 Jun 21; 17(3):145-54. PubMed ID: 22615190
    [Abstract] [Full Text] [Related]

  • 19. [Experiences with solcoseryl in treatment of stage II peripheral arterial occlusive disease--assessment of clinical effectiveness].
    Horsch S, Claeys L.
    Vasa Suppl; 1992 Jun 21; 35():151-2. PubMed ID: 1481024
    [No Abstract] [Full Text] [Related]

  • 20. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial.
    Arosio E, De Marchi S, Zannoni M, Prior M, Lechi A.
    Mayo Clin Proc; 2002 Aug 21; 77(8):754-9. PubMed ID: 12173710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.